Viking Therapeutics Inc
VKTX31.630USD
+0.930+3.03%
收盤 07/16, 16:00（美東）報價延遲15分鐘
3.55B總市值
虧損本益比TTM
關於 Viking Therapeutics Inc 公司
Viking Therapeutics, Inc. 是一家臨牀階段的生物製藥公司，專注於開發治療代謝和內分泌疾病的療法。該公司的臨牀項目包括 VK2809，這是一種口服小分子選擇性甲狀腺激素受體 β 激動劑，用於治療脂質和代謝疾病，目前正在進行 II b 期研究，以評估其治療活檢證實的非酒精性脂肪性肝炎 (NASH) 和纖維化的效果。該公司正在開發 VK0214，這也是一種口服組織和受體亞型選擇性 TRb 激動劑，用於治療 X 連鎖腎上腺腦白質營養不良 (X-ALD)，這是一種罕見的 X 連鎖遺傳性神經系統疾病，其特徵是大腦和神經細胞周圍的保護屏障被破壞。該公司還在開發 VK2735，這是胰高血糖素樣肽 1 (GLP-1) 和葡萄糖依賴性胰島素促泌多肽 (GIP) 受體的雙重激動劑，用於治療各種代謝紊亂。
公司簡介
公司代碼VKTX
公司名稱Viking Therapeutics Inc
上市日期Apr 29, 2015
成立日期2012
CEODr. Brian W. Lian, Ph.D.
員工數量36
證券類型Ordinary Share
年結日Apr 29
公司地址9920 Pacific Heights Blvd, Suite 350
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編92121
電話18587044660
網址https://vikingtherapeutics.com/
公司代碼VKTX
上市日期Apr 29, 2015
成立日期2012
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Lawson Macartney, Ph.D.
Dr. Lawson Macartney, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
47.97K
--
Mr. Greg Zante, CPA
Mr. Greg Zante, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marianne Mancini
Ms. Marianne Mancini
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
Independent Director
Independent Director
--
--
Dr. S. Kathy Rouan, Ph.D.
Dr. S. Kathy Rouan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles A. (Charlie) Rowland, Jr.
Mr. Charles A. (Charlie) Rowland, Jr.
Independent Director
Independent Director
--
--
Mr. J. Matthew Singleton, CPA
Mr. J. Matthew Singleton, CPA
Independent Director
Independent Director
--
--
Dr. Brian W. Lian, Ph.D.
Dr. Brian W. Lian, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Lawson Macartney, Ph.D.
Dr. Lawson Macartney, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
47.97K
--
Mr. Greg Zante, CPA
Mr. Greg Zante, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marianne Mancini
Ms. Marianne Mancini
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
Independent Director
Independent Director
--
--
Dr. S. Kathy Rouan, Ph.D.
Dr. S. Kathy Rouan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles A. (Charlie) Rowland, Jr.
Mr. Charles A. (Charlie) Rowland, Jr.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
9.11%
The Vanguard Group, Inc.
9.03%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.61%
JP Morgan Asset Management
2.41%
Other
71.51%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
9.11%
The Vanguard Group, Inc.
9.03%
BlackRock Institutional Trust Company, N.A.
4.34%
State Street Global Advisors (US)
3.61%
JP Morgan Asset Management
2.41%
Other
71.51%
股東類型
持股股東
佔比
Investment Advisor
29.46%
Investment Advisor/Hedge Fund
24.98%
Hedge Fund
8.22%
Research Firm
4.13%
Individual Investor
2.15%
Sovereign Wealth Fund
1.14%
Bank and Trust
0.77%
Pension Fund
0.74%
Private Equity
0.45%
Other
27.95%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
859
81.00M
72.12%
-18.38M
2025Q1
881
81.93M
72.95%
-19.61M
2024Q4
837
90.73M
82.19%
-16.87M
2024Q3
781
90.59M
82.61%
-15.25M
2024Q2
701
89.78M
82.34%
-10.20M
2024Q1
634
89.55M
82.55%
-7.02M
2023Q4
464
85.12M
85.96%
-16.14M
2023Q3
442
85.70M
86.63%
-10.01M
2023Q2
426
82.52M
83.46%
-982.32K
2023Q1
408
74.30M
93.67%
+22.84M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
10.23M
9.11%
-6.28M
-38.05%
Mar 31, 2025
The Vanguard Group, Inc.
10.14M
9.03%
-8.18K
-0.08%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.87M
4.34%
+31.60K
+0.65%
Mar 31, 2025
State Street Global Advisors (US)
4.06M
3.61%
-870.07K
-17.66%
Mar 31, 2025
JP Morgan Asset Management
2.70M
2.41%
+664.27K
+32.59%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.98M
1.77%
+103.68K
+5.51%
Mar 31, 2025
Lian (Brian)
1.92M
1.71%
-446.09K
-18.85%
Mar 15, 2025
Pictet Asset Management Ltd.
1.92M
1.71%
+684.34K
+55.32%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.79M
1.6%
+412.62K
+29.89%
Mar 31, 2025
Susquehanna International Group, LLP
1.68M
1.49%
+643.39K
+62.26%
Mar 31, 2025
查看更多
持股ETF
更新時間: 7月6日 週日
更新時間: 7月6日 週日
機構名稱
佔比
Roundhill GLP-1 & Weight Loss ETF
4.14%
Formidable ETF
1.56%
Amplify Weight Loss Drug & Treatment ETF
1.33%
SPDR S&P Biotech ETF
1.09%
Tema Heart & Health ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
Direxion Daily S&P Biotech Bull 3X Shares
0.72%
Nuveen ESG Small-Cap ETF
0.33%
Amplify AI Powered Equity ETF
0.26%
Inspire Small/Mid Cap ESG ETF
0.24%
查看更多
Roundhill GLP-1 & Weight Loss ETF
佔比4.14%
Formidable ETF
佔比1.56%
Amplify Weight Loss Drug & Treatment ETF
佔比1.33%
SPDR S&P Biotech ETF
佔比1.09%
Tema Heart & Health ETF
佔比1%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.87%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.72%
Nuveen ESG Small-Cap ETF
佔比0.33%
Amplify AI Powered Equity ETF
佔比0.26%
Inspire Small/Mid Cap ESG ETF
佔比0.24%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
